Satellos Bioscience shares are trading higher after the company announced that the FDA has granted Fast Track designation to SAT-3247 for the treatment of Duchenne.

Benzinga Newsdesk www.benzinga.com Positive 95.3%

Neg 0% Neu 0% Pos 95.3%

Comments

No comments yet. Be the first!